Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-800CW Fluorescence Endoscopy in Esophageal Cancer
NCT03558724Phase 1Terminated
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2018
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of bevacizumab-IRDye800CW in esophageal cancer (3 arms), sponsored by University Medical Center Groningen. Primary endpoints: Discrimination of tumorous and non-tumorous tissue based on in vivo and ex vivo fluorescence measurements and Safety of bevacizumab-800CW administration. Started Oct 2018; status: terminated.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03558724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03558724.